KRAS and gastric cancer: This finding demonstrates that KRAS activation alone is insufficient for malignant transformation, consistent with human gastric cancer where KRAS mutations are typically accompanied by additional genetic alterations such as TP53, APC, or phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha mutations.